Cingulate Completes Financing Transaction for Net Proceeds of 5,000,000
CING Stock | USD 4.86 0.10 2.10% |
Roughly 55% of Cingulate's stockholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Cingulate suggests that some traders are interested. The current market sentiment, together with Cingulate's historical and current headlines, can help investors time the market. In addition, many technical investors use Cingulate stock news signals to limit their universe of possible portfolio assets.
Cingulate |
Cash Runway Extended Beyond Planned NDA Submission of CTx-1301KANSAS CITY, Kan., Dec. 23, 2024 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has completed a financing transaction with an accredited investor which provided net proceeds to CING of 5 million. The transaction was structured as a non-c
Read at finance.yahoo.com
Cingulate Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cingulate can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cingulate Fundamental Analysis
We analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Cingulate is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Cingulate Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cingulate stock to make a market-neutral strategy. Peer analysis of Cingulate could also be used in its relative valuation, which is a method of valuing Cingulate by comparing valuation metrics with similar companies.
Peers
Cingulate Related Equities
ANEB | Anebulo Pharmaceuticals | 26.26 | ||||
ANTX | AN2 Therapeutics | 11.11 | ||||
SNTI | Senti Biosciences | 4.25 | ||||
ADAG | Adagene | 3.19 | ||||
GNLX | Genelux Common | 1.32 | ||||
AVTE | Aerovate Therapeutics | 1.19 | ||||
RZLT | Rezolute | 1.14 | ||||
PMVP | Pmv Pharmaceuticals | 0.67 | ||||
DYAI | Dyadic International | 2.79 | ||||
ACRV | Acrivon Therapeutics, | 3.62 | ||||
IKT | Inhibikase Therapeutics | 7.50 | ||||
MNPR | Monopar Therapeutics | 8.12 |
Complementary Tools for Cingulate Stock analysis
When running Cingulate's price analysis, check to measure Cingulate's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cingulate is operating at the current time. Most of Cingulate's value examination focuses on studying past and present price action to predict the probability of Cingulate's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cingulate's price. Additionally, you may evaluate how the addition of Cingulate to your portfolios can decrease your overall portfolio volatility.
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |